Fractyl Health's Rejuva pancreatic gene therapy program aims to combat rebound weight gain after stopping GLP-1 drugs for obesity.

The therapy integrates a GLP-1-secreting transgene into pancreatic cells, maintaining weight loss benefits in a mouse model.

Rejuva was found to be nutrient-responsive and effective at low doses, potentially reducing toxicity risks.

Clinical studies for diabetes are scheduled for 2025, with an obesity candidate expected to be nominated by the end of 2024.

Localized delivery of Rejuva may offer a more cost-effective alternative to chronic GLP-1 drugs for managing obesity and type 2 diabetes.